| Literature DB >> 35545089 |
Hyejin Park1, Tae-In Kam1, Hanjing Peng2, Shih-Ching Chou3, Amir A Mehrabani-Tabari4, Jae-Jin Song5, Xiling Yin5, Senthilkumar S Karuppagounder5, George K Umanah5, A V Subba Rao2, YuRee Choi5, Akanksha Aggarwal4, Sohyun Chang4, Hyunhee Kim5, Jiyoung Byun4, Jun O Liu2, Ted M Dawson6, Valina L Dawson7.
Abstract
Parthanatos-associated apoptosis-inducing factor (AIF) nuclease (PAAN), also known as macrophage migration inhibitor factor (MIF), is a member of the PD-D/E(X)K nucleases that acts as a final executioner in parthanatos. PAAN's role in Parkinson's disease (PD) and whether it is amenable to chemical inhibition is not known. Here, we show that neurodegeneration induced by pathologic α-synuclein (α-syn) occurs via PAAN/MIF nuclease activity. Genetic depletion of PAAN/MIF and a mutant lacking nuclease activity prevent the loss of dopaminergic neurons and behavioral deficits in the α-syn preformed fibril (PFF) mouse model of sporadic PD. Compound screening led to the identification of PAANIB-1, a brain-penetrant PAAN/MIF nuclease inhibitor that prevents neurodegeneration induced by α-syn PFF, AAV-α-syn overexpression, or MPTP intoxication in vivo. Our findings could have broad relevance in human pathologies where parthanatos plays a role in the development of cell death inhibitors targeting the druggable PAAN/MIF nuclease.Entities:
Keywords: MIF; PARP1; Parkinson’s disease; cell death; neurodegeneration; parthanatos; synuclein
Mesh:
Substances:
Year: 2022 PMID: 35545089 PMCID: PMC9149120 DOI: 10.1016/j.cell.2022.04.020
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 66.850